Eagle Bay Advisors LLC Sells 159 Shares of Eli Lilly and Company (NYSE:LLY)

Eagle Bay Advisors LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 17.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 765 shares of the company’s stock after selling 159 shares during the quarter. Eagle Bay Advisors LLC’s holdings in Eli Lilly and Company were worth $692,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Atomi Financial Group Inc. increased its position in shares of Eli Lilly and Company by 11.6% during the second quarter. Atomi Financial Group Inc. now owns 5,283 shares of the company’s stock worth $4,783,000 after purchasing an additional 550 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in Eli Lilly and Company by 1.5% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 167,879 shares of the company’s stock worth $151,994,000 after purchasing an additional 2,446 shares in the last quarter. RiverPark Advisors LLC grew its holdings in shares of Eli Lilly and Company by 5.8% in the second quarter. RiverPark Advisors LLC now owns 2,455 shares of the company’s stock valued at $2,223,000 after purchasing an additional 134 shares during the period. Riverpark Capital Management LLC boosted its stake in Eli Lilly and Company by 7.9% during the second quarter. Riverpark Capital Management LLC now owns 2,354 shares of the company’s stock worth $2,131,000 after buying an additional 173 shares during the period. Finally, Dearborn Partners LLC boosted its holdings in Eli Lilly and Company by 0.8% during the 2nd quarter. Dearborn Partners LLC now owns 4,648 shares of the company’s stock valued at $4,208,000 after acquiring an additional 37 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Down 0.5 %

Shares of NYSE:LLY traded down $5.23 on Wednesday, reaching $949.25. The company had a trading volume of 697,186 shares, compared to its average volume of 3,075,214. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The firm’s 50 day simple moving average is $887.63 and its 200-day simple moving average is $816.72. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $902.17 billion, a PE ratio of 140.80, a PEG ratio of 1.81 and a beta of 0.41.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now directly owns 25,428 shares in the company, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,120,089 shares of company stock worth $990,278,343. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Argus raised their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, August 19th. Barclays boosted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $961.76.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.